The Association of the Cholesterol Efflux Capacity with the Paraoxonase 1 Q192R Genotype and the Paraoxonase Activity

Overview

Journal J Atheroscler Thromb

Date 2024 Mar 20

PMID 38508740

Authors

Kentaro Oniki

Kayoko Ohura

Megumi Endo

Daniel Akatwijuka

Erika Matsumoto

Teruya Nakamura

Yasuhiro Ogata

Minoru Yoshida

Mariko Harada-Shiba

Junji Saruwatari

Masatsune Ogura

Teruko Imai

Affiliations

Soon will be listed here.

Abstract

Aims: Paraoxonase 1 (PON1) binds to high-density lipoprotein (HDL) and protects against atherosclerosis. However, the relationship between functional PON1 Q192R polymorphism, which is associated with the hydrolysis of paraoxon (POXase activity) and atherosclerotic cardiovascular disease (ASCVD), remains controversial. As the effect of PON1 Q192R polymorphism on the HDL function is unclear, we investigated the relationship between this polymorphism and the cholesterol efflux capacity (CEC), one of the biological functions of HDL, in association with the PON1 activity.

Methods: The relationship between PON1 Q192R polymorphisms and CEC was investigated retrospectively in 150 subjects without ASCVD (50 with the PON1 Q/Q genotype, 50 with the Q/R genotype, and 50 with the R/R genotype) who participated in a health screening program. The POXase and arylesterase (AREase: hydrolysis of aromatic esters) activities were used as measures of the PON1 activity.

Results: The AREase activity was positively correlated with CEC independent of the HDL cholesterol levels. When stratified by the PON1 Q192R genotype, the POXase activity was also positively correlated with CEC independent of HDL cholesterol. PON1 Q192R R/R genotype carriers had a lower CEC than Q/Q or Q/R genotype carriers, despite having a higher POXase activity. Moreover, in a multiple regression analysis, the PON1 Q192R genotype was associated with the degree of CEC, independent of the HDL cholesterol and POXase activity.

Conclusions: The PON1 Q192R R allele is associated with reduced CEC in Japanese people without ASCVD. Further studies on the impact of this association on the severity of atherosclerosis and ASCVD development are thus called for.

Citing Articles

Determination of selected oxysterol levels, oxidative stress, and macrophage activation indicators in children and adolescents with familial hypercholesterolemia.

Canbay E, Canda E, Yazici H, Kasikci G, Durmaz B, Copur O Lipids Health Dis. 2024; 23(1):374.

PMID: 39538217 PMC: 11562613. DOI: 10.1186/s12944-024-02371-y.

PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles.

Trentini A, Rosta V, Riccetti R, Mola G, Galletti R, Pinotti M Antioxidants (Basel). 2024; 13(10).

PMID: 39456469 PMC: 11505261. DOI: 10.3390/antiox13101216.

Genetic Determinants of High-density Lipoprotein Cholesterol Efflux Capacity: Insights from Paraoxonase 1 Polymorphisms.

Toh R J Atheroscler Thromb. 2024; 31(9):1260-1262.

PMID: 38910119 PMC: 11374540. DOI: 10.5551/jat.ED267.

References

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R . Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004; 11(5):412-9. DOI: 10.1038/nsmb767. View

Rosenblat M, Karry R, Aviram M . Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2005; 187(1):74-81. DOI: 10.1016/j.atherosclerosis.2005.08.026. View

Ko D, Alter D, Guo H, Koh M, Lau G, Austin P . High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol. 2016; 68(19):2073-2083. DOI: 10.1016/j.jacc.2016.08.038. View

Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E . A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res. 2000; 41(8):1358-63. View

Gaidukov L, Rosenblat M, Aviram M, Tawfik D . The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006; 47(11):2492-502. DOI: 10.1194/jlr.M600297-JLR200. View

Bhattacharyya T, Nicholls S, Topol E, Zhang R, Yang X, Schmitt D . Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008; 299(11):1265-76. PMC: 3014051. DOI: 10.1001/jama.299.11.1265. View

Hernandez-Diaz Y, Tovilla-Zarate C, Juarez-Rojop I, Gonzalez-Castro T, Rodriguez-Perez C, Lopez-Narvaez M . Effects of paraoxonase 1 gene polymorphisms on heart diseases: Systematic review and meta-analysis of 64 case-control studies. Medicine (Baltimore). 2016; 95(44):e5298. PMC: 5591151. DOI: 10.1097/MD.0000000000005298. View

Kjeldsen E, Thomassen J, Frikke-Schmidt R . HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1867(1):159063. DOI: 10.1016/j.bbalip.2021.159063. View

Furuhashi M, Ogura M, Matsumoto M, Yuda S, Muranaka A, Kawamukai M . Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages. Sci Rep. 2017; 7(1):217. PMC: 5427929. DOI: 10.1038/s41598-017-00177-w. View

10.

Shao B, Cavigiolio G, Brot N, Oda M, Heinecke J . Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A. 2008; 105(34):12224-9. PMC: 2527893. DOI: 10.1073/pnas.0802025105. View

11.

Madsen C, Varbo A, Nordestgaard B . Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017; 38(32):2478-2486. DOI: 10.1093/eurheartj/ehx163. View

12.

Keene D, Price C, Shun-Shin M, Francis D . Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014; 349:g4379. PMC: 4103514. DOI: 10.1136/bmj.g4379. View

13.

Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M . Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004; 318(3):680-3. DOI: 10.1016/j.bbrc.2004.04.056. View

14.

Haase C, Tybjaerg-Hansen A, Qayyum A, Schou J, Nordestgaard B, Frikke-Schmidt R . LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2011; 97(2):E248-56. DOI: 10.1210/jc.2011-1846. View

15.

Deakin S, Bioletto S, Bochaton-Piallat M, James R . HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med. 2010; 50(1):102-9. DOI: 10.1016/j.freeradbiomed.2010.09.002. View

16.

Shih D, Gu L, Xia Y, Navab M, Li W, Hama S . Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998; 394(6690):284-7. DOI: 10.1038/28406. View

17.

Chen H, Li S, Chen L, Wang W, Wang Y, Yan X . The effects of cigarette smoking and smoking cessation on high-density lipoprotein functions: implications for coronary artery disease. Ann Clin Biochem. 2018; 56(1):100-111. DOI: 10.1177/0004563218788386. View

18.

Ogura M, Hori M, Harada-Shiba M . Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2015; 36(1):181-8. DOI: 10.1161/ATVBAHA.115.306665. View

19.

Luo J, Ren H, Liu M, Fang P, Xiang D . European versus Asian differences for the associations between paraoxonase-1 genetic polymorphisms and susceptibility to type 2 diabetes mellitus. J Cell Mol Med. 2018; 22(3):1720-1732. PMC: 5824408. DOI: 10.1111/jcmm.13453. View

20.

Mackness B, Mackness M, Arrol S, Turkie W, Durrington P . Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998; 423(1):57-60. DOI: 10.1016/s0014-5793(98)00064-7. View